RevitalVision vision-training software
Digital Health News

Groundbreaking Study by Dr. Agarwal’s Eye Hospital on post-crosslinking surgery patients Wins ‘Best Scientific Poster Award’ at ASCRS 2024 Annual Meeting

Dr Agarwal’s Eye Hospital recently announced that their accomplished research team have been honoured with the prestigious ‘Best Scientific Poster Award’ at the 2024 Annual Meeting of the American Society for Cataract and Refractive Surgery (ASCRS). This recognition comes in light of their groundbreaking study on ‘The efficacy of RevitalVision vision-training software in improving best-corrected […]

"PressureSafe Technology Demonstration"
Digital Health News

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital, and Rabin Medical Center, both in Petah Tikva and owned by Clalit, the world’s second […]

Hēlo Thrombectomy System - ENGULF Pivotal Trial FDA Approval
Device Digest

Endovascular Engineering’s Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism

Endovascular Engineering (“E2”), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE), announced today FDA Investigational Device Exemption (IDE) approval for its ENGULF US pivotal trial. This study will evaluate the safety and effectiveness of the Hēlo Thrombectomy System in treating pulmonary embolism (PE), […]

Digital Health News

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

PharmAbcine, Inc. (“PharmAbcine” or the “Company”) (KOSDAQ: 208340), a clinical-stage public company focused on developing novel antibody therapies for patients, today announced that the Safety Review Committee (SRC) has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose level 1 safety data evaluation. […]

Drug Updates

First patient treated in the second dose group in Annexin’s RVO study

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company’s clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No limiting treatment-related side effects have been reported and the company has received recommendation to proceed […]

Digital Health News

Clinical Study Conducted at Medical University of South Carolina Finds Synchrony Medical’s LibAirty™ Airway Clearance System Highly Effective for Chronic Lung Disease Patients

The results of a clinical study of Synchrony Medical’s LibAirty™ Airway Clearance System showed that the system was twice as effective in clearing mucus from the lungs of patients with chronic lung disease when compared to the standard of care therapy. The findings were announced in an oral presentation at CHEST2023 in Honolulu, Hawaii. The study, led […]

ALRT Technologies logo
Device Digest

ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study

ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan (“Predictive A1c”) has been granted in Singapore and has received notice of allowance in the United States. Predictive A1c is the Company’s cornerstone, the first of its […]

HANSIZHUANG Approval for ESCC Treatment
Drug Updates

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous cell […]

Woman finding relief from menstrual cramps with Rhuleave-K®
Drug Updates

Arjuna Natural’s Turmeric–Frankincense Botanical Blend Relieves Menstrual Pain in Clinical Study

Kerala, India – A novel botanical formula powered by turmeric (Curcuma longa L), and frankincense (Boswellia serrata) has demonstrated abilities to alleviate menstrual cramps in a new clinical study. Rhuleave-K®, a breakthrough blend composed by the renowned nutraceutical company Arjuna Natural Pvt. Ltd., is poised to offer a natural holistic solution to   manage menstrual discomfort, […]